Cross-Sector entity
Coverage clusters in regulation, which accounts for 13 of those 15, with the remainder spread across 2 other categories. Duane Boise is most often covered alongside MMJ International Holdings, Inc., which appears in 8 of these 15 stories. The 36-day window averages about 2.9 stories each week. The busiest single day carried 4.
15 verified stories tracked
Last mentioned: Aug 16, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 6 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Coverage clusters in regulation, which accounts for 13 of those 15, with the remainder spread across 2 other categories. Duane Boise is most often covered alongside MMJ International Holdings, Inc., which appears in 8 of these 15 stories. The 36-day window averages about 2.9 stories each week. The busiest single day carried 4. Duane Boise appears in 15 tracked Cross-Sector stories published from July 12, 2026 through August 16, 2026. The tracked stories average 2 original sources each. 33% of these stories carry negative sentiment.
Computed from the 15 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Duane Boise. Shared-story counts are live from our verified record — not editorial picks.
Post-Hearing Briefs Due
Parties submit final briefs to Administrative Law Judge Derek C. Julius, summarizing their arguments on the evidentiary record and legal standards. The recommendation on rescheduling is expected to follow shortly thereafter.
MMJ International Holdings issues legal warning
MMJ said that operational implementation of the administration's cannabis agenda does not equal legal finality and that its federal challenges could yield a stay, remand, vacatur, or targeted relief.
CNBC reports cannabis as emerging midterm issue
A CNBC report highlighted marijuana policy as an emerging 2026 midterm issue, noting ballot measures in Massachusetts and Idaho and gubernatorial races in Kansas and Iowa.
Senate Democrats reintroduce Cannabis Administration and Opportunity Act
17 Senate Democrats reintroduced the CAOA, maintaining federal cannabis reform pressure while administrative actions proceed.
Rescheduling Hearing Testimony
Under subpoena, Dr. Akinfiresoye testifies in the marijuana rescheduling proceeding that marijuana fails the first three factors of the DEA's five-factor test, directly contradicting the HHS Schedule III recommendation.
ALJ Hearing on Marijuana Rescheduling
A seven-day administrative hearing is held in Arlington, Virginia, debating whether marijuana has a 'currently accepted medical use' without MMJ's testimony or evidence.
MMJ announces advancement of legal challenge
Company issues press release declaring that the D.C. Circuit challenge has advanced and that the operative legal event is the court review, not the upcoming DEA hearing.
Statement of Issues filed
MMJIH files a Statement of Issues in the D.C. Circuit Court of Appeals seeking vacatur of the Final Order.
DEA Excludes MMJ from Rescheduling Hearing
The DEA denies MMJ International Holdings' request to participate in the upcoming administrative hearing, asserting that its evidence raises only questions of law.
Acting Attorney General issues Final Order
Todd Blanche places marijuana into Schedule III of the Controlled Substances Act via a Final Order.
Attorney General orders marijuana moved to Schedule III
The AG issues an order rescheduling state‑licensed medical marijuana and establishing a novel federal registration system for state marijuana businesses.
Initial DEA hearing process begins
A hearing process on marijuana rescheduling begins under the Controlled Substances Act, later terminated by the government according to petitioners.
DEA Scientific Data Review Published
Dr. Luli Akinfiresoye authors the DEA's internal Scientific Data Review on marijuana, reportedly concluding that marijuana lacks sufficient, reproducible scientific evidence for accepted medical use.
MMJ files DEA bulk‑manufacturer application
MMJ International Holdings submits an application to manufacture active pharmaceutical ingredients for cannabinoid drugs, which remains pending nearly eight years later.
For legal and regulatory professionals, MMJ's statement exposes the volatile gap between administrative implementation and judicial finality. The dispute could generate stay, remand, or vacatur rulings that determine whether operators can rely on current federal cannabis policies.
Health systems and health IT vendors building around CMS's hemp-derived cannabinoid initiative are on contested regulatory ground. A successful federal challenge could stay or remand the program, changing compliance and reimbursement calculations.
Investors and lenders in cannabis and hemp face event risk from MMJ's federal challenges to the administration's accelerated policies. Current 280E tax relief and DEA registration activity may be reversed if courts intervene.
Biotech and pharma teams evaluating cannabinoid-derived drugs face unsettled federal scheduling and reimbursement policy. MMJ's litigation could alter DEA and CMS pathways through stay, remand, or vacatur.
Source: finanznachrichten.de · pr-inside.com
ALJ Julius's upcoming recommendation in the DEA marijuana rescheduling hearing may challenge the government's novel approach of limiting Schedule III status to state-licensed medical programs, after DEA scientist testimony cast doubt on whether such programs satisfy the Controlled Substances Act's rigorous medical-use standard.
Source: nashvilleherald.com · pittsburghstar.com
A D.C. Circuit review of the Attorney General’s April 2026 order moving medical marijuana to Schedule III puts administrative law front and center. MMJ International Holdings argues the AG skipped required rulemaking and evidentiary hearings, threatening the integrity of the Controlled Substances Act’s scheduling process.
Investors face renewed uncertainty as a federal court considers whether the Attorney General acted improperly in moving state medical marijuana to Schedule III. An adverse ruling could unwind tax and banking benefits that have underpinned bullish cannabis investment theses, potentially erasing billions in market capitalization.
DEA pharmacologist Dr. Luli Akinfiresoye testified that marijuana fails the agency's historical scientific standard for accepted medical use, directly contradicting the HHS recommendation to reschedule. This intra-agency conflict exposes the proposed Schedule III rule to a likely arbitrary-and-capricious challenge, redefining the evidentiary landscape for controlled substance rulemaking.
Source: newjerseytelegraph.com · pr-inside.com
The MMJ International Holdings petition raises fundamental administrative law questions: can an agency issue a final rescheduling order before conducting the hearing required by the Controlled Substances Act? The D.C. Circuit’s answer will shape DEA’s authority over all future scheduling actions.
MMJ International Holdings' appeal to the D.C. Circuit exposes a procedural flaw in the DEA's marijuana rescheduling that could delay patient access to new cannabinoid medicines and create confusion for healthcare providers trying to navigate the shifting regulatory landscape.
Source: tennesseedaily.com · pr-inside.com
MMJ International Holdings alleges the DEA violated administrative law by excluding it from marijuana rescheduling hearings, despite spending $10 million on FDA-pathway development. The exclusion raises due process and APA concerns that could imperil the final rule.
Source: saltlakecitysun.com · memphissun.com
Investors are watching the D.C. Circuit case closely as MMJ International Holdings claims marijuana rescheduling would deliver over $2 billion in annual tax savings to multi-state operators, potentially boosting profitability and stock prices.
MMJ International Holdings' latest filing reveals that up to $2.24 billion in annual 280E tax overpayments could be reversed, plus $1.6B in accrued unpaid taxes forgiven—a sum that would transform balance sheets for cash-strapped cannabis startups.
The potential elimination of 280E taxes on cannabis businesses could inject over $2 billion annually into the biotech sector, accelerating cannabinoid drug development. MMJ International Holdings' latest press release quantifies the stakes.
MMJ International Holdings says moving cannabis to Schedule III would wipe out $2.24B in annual excess 280E taxes, unlocking capital for patient programs and medical research. The legal dispute spotlights the massive healthcare economic stakes of drug scheduling.
Source: finanznachrichten.de
